Latest Therapeutics News

Syntara Limited has reported encouraging Phase 2a results for amsulostat combined with ruxolitinib in treating myelofibrosis, demonstrating sustained symptom improvement and spleen volume reduction over 52 weeks.

Nyrada Inc. has announced successful Phase I trial results for its lead drug candidate Xolatryp, confirming safety and pharmacokinetics that pave the way for a Phase IIa trial targeting heart attack patients next year.

Chimeric Therapeutics reports encouraging early clinical trial outcomes for its CHM CDH17 CAR-T therapy, showing disease control and tumour shrinkage at higher dose levels with a strong safety profile.

Invex Therapeutics has voluntarily suspended trading on the ASX pending a significant acquisition announcement and responses to a price query. The suspension is expected to last until the announcement or early next week.

Cann Group Limited has reported its first-ever EBITDA-positive month in August 2025, driven by strong B2B flower sales and disciplined cost management. The company is advancing export negotiations in Europe and preparing to launch a new Botanitech product range.

Arovella Therapeutics has received a $3.21 million R&D tax incentive refund, bolstering its financial position as it prepares to initiate first-in-human trials for its lead cell therapy, ALA-101.

Algorae Pharmaceuticals has secured an exclusive licensing agreement with Sakar Healthcare to introduce five generic oncology medicines in Australia and New Zealand, marking its first commercial foray in the region.

INOVIQ Limited has demonstrated that its CAR-NK-exosome therapy kills over 90% of triple-negative breast cancer cells within 10 hours in laboratory tests, validating its potential as a next-generation cancer treatment.

Starpharma has entered a significant collaboration with Genentech to develop dendrimer-drug conjugates for oncology, securing an upfront payment and potential milestone earnings exceeding half a billion dollars.

PYC Therapeutics has restructured its Board and executive team to steer the company through pivotal clinical milestones expected by the end of 2027. The changes signal a strategic push toward late-stage development of its RNA-based drug candidates.

EVE Health Group has begun distributing Dyspro™, a novel cannabinoid-based treatment for dysmenorrhoea and endometriosis, through a national telehealth partnership. This launch targets a significant unmet need in women’s health with a growing global market.

CLINUVEL Pharmaceuticals has presented compelling new case studies demonstrating the efficacy of SCENESSE® in treating vitiligo, showing significant and stable repigmentation in patients. These findings, shared at the EADV conference, hint at a potential breakthrough for a condition with limited treatment options.